B7-4 polypeptides and uses therefor

• US 7,038,013 B2
• Filed: 11/02/2001
• Issued: 05/02/2006
• Est. Priority Date: 08/23/1999
• Status: Expired due to Term

• Current Assignee: Dana-Farber Cancer Institute
• Original Assignee: Dana-Farber Cancer Institute
• Inventors: Malenkovich, Nelly, Chernova, Tatyana, Freeman, Gordon, Boussiotis, Vassiliki
• Primary Examiner(s): Gambel, Phillip
• Assistant Examiner(s): OUSPENSKI, ILIA I
• Application Number:
  US10/002,775
• Publication Number:
  US 20020102651A1
• Time in Patent Office: 1,642 Days
• Field of Search: 530/350, 530/351, 530/387.3
• US Class Current: 530/350
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 14/70532 B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Claims

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:

2 or 4.

2. The polypeptide of claim 1, further comprising heterologous amino acid sequences.

3. The polypeptide of claim 2, wherein the heterologous amino acid sequences are from an immunoglobulin molecule.

4. An isolated polypeptide comprising from about amino acid residue 19 to amino acid residue 245 of SEQ ID NO:

2 or from about amino acid residue 19 to amino acid residue 238 of SEQ ID NO;

4.

5. An isolated polypeptide encoded by a nucleic acid molecule which hybridizes over its full-length under conditions of incubation at 45°

C. in 6×

sodium chloride/sodium citrate(SSC), followed by washing in 0.2×

SSC, 0.1% SDS, at 50–

65°

C. to the complement of a nucleic acid molecule of SEQ ID NO;

1 or 3, wherein the polypeptide costimulates T cell proliferation in vitro when the polypeptide is present on a first surface and a molecule that transmits an activating signal via the T cell receptor is present on a second, different surface.

6. The polypeptide of claim 5, further comprising heterologous amino acid sequences.

7. The polypeptide of claim 6, wherein the heterologous amino acid sequences are from an immunoglobulin molecule.

8. An isolated polypeptide encoded by a nucleic acid molecule having a nucleotide sequence at least about 95% identical to the nucleotide sequence of SEQ ID NO:

1 or 3, wherein the polypeptide costimulates T cell proliferation in vitro when the polypeptide is present on a first surface and a molecule that transmits an activating signal via the T cell receptor is present on a second, different surface.

9. The polypeptide of claim 8, further comprising heterologous amino acid sequences.

10. The polypeptide of claim 9, wherein the heterologous amino acid sequences are from an immunoglobulin molecule.

11. An isolated polypeptide comprising an amino acid sequence at least about 95% identical to the amino acid sequence of SEQ ID NO:

2 or 4, wherein the polypeptide costimulates T cell proliferation in vitro when the polypeptide is present on a first surface and a molecule that transmits an activating signal via the T cell receptor is present on a second, different surface.

12. The polypeptide of claim 11, further comprising heterologous amino acid sequences.

13. The polypeptide of claim 12, wherein the heterologous amino acid sequences are derived from an immunoglobulin molecule.

14. An isolated polypeptide comprising from about amino acid residue 19 to amino acid residue 227 of SEQ ID NO:

4.